Clinical trials: Kidney Insufficiency
Renal Impairment
Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females
PK and safety profile of Proellex® in females with various stages of impaired renal function
- Trial name
- NCT00787618
- Testing
- 50 mg Proellex
- Where
- 4 sites in United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02378662
- Testing
- MDGN201 TARGTEPO
- Where
- 2 sites in Israel
- Volunteers
- 2 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Chronic Kidney Disease
A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)
This research study is designed to assess the safety and effectiveness of an experimental drug called PRT-201 in patients both receiving or expecting to receive dialysis who have chronic kidney disease and who are undergoing…
- Trial name
- NCT02110901
- Testing
- PRT-201
- Where
- 35 sites in United States
- Volunteers
- 349 people
- Sponsor
- Proteon Therapeutics
Hyperkalemia
Patiromer With or Without Food for the Treatment of Hyperkalemia
The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high…
- Trial name
- TOURMALINE (NCT02694744)
- Testing
- patiromer
- Where
- 29 sites in United States
- Volunteers
- 114 people
- Sponsor
- Relypsa, Inc.
Renal Insufficiency, Chronic
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
The study to be conducted is a prospective, open label trial. It is designed to evaluate the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran etexilate in patients with chronic kidney disease.
- Trial name
- NCT01711853
- Testing
- Dabigatran Etexilate
- Where
- Netherlands
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Anaemia, Chronic Kidney Disease (CKD)
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
To describe anaemia correction via haemoglobin measurements taken throughout observation period in ESA naive patients with chronic kidney disease initiated on darbepoetin alfa QM
- Trial name
- ADAPTATION (NCT02185911)
- Where
- 40 sites in Austria, Bulgaria and 6 more
- Volunteers
- 308 people
- Sponsor
- Amgen
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Diabetic Nephropathy
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.
- Trial name
- NCT00920764
- Testing
- 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Cognitive Impairment, End Stage Renal Disease
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
- Trial name
- NCT04527328
- Testing
- AKST1210, Hemodialysis
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alkahest, Inc.
Hepatitis B
A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease
The purpose of this study is to find out if a new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™, is safe and effective for end-stage renal disease (ESRD) patients.
- Trial name
- NCT00498212
- Testing
- 1018 ISS-HBsAg-Single, 1018 ISS-HBsAg-Double
- Where
- 3 sites in Canada
- Volunteers
- 41 people
- Sponsor
- Dynavax Technologies Corporation
Chronic Kidney Disease
Renal Impairment Study for Oral EC5026
The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1.
- Trial name
- NCT07694544
- Testing
- EC5026 oral tablet
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- EicOsis Human Health Inc.
Liver Cirrhosis
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.
- Trial name
- NCT06715670
- Testing
- Zibotentan
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetic Kidney Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients
The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.
- Trial name
- NCT06666283
- Testing
- AP303 150μg
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Alebund Pharmaceuticals
Diabetic Kidney Disease, CAKUT
A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
- Conditions
- Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases
- Trial name
- NCT05694169
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Prokidney
Anemia of Chronic Kidney Disease
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
This is a multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the efficacy of vadadustat administered three times a week compared to standard of care erythropoiesis-stimulating agent for the…
- Trial name
- NCT06901505
- Testing
- Erythropoiesis-Stimulating Agent (ESA), Vadadustat
- Where
- 18 sites in United States
- Volunteers
- 353 people
- Sponsor
- Akebia Therapeutics
Kidney Disease, Chronic
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice.
- Trial name
- NCT06287073
- Testing
- JARDIANCE®
- Where
- 12 sites in South Korea
- Volunteers
- 299 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.
- Trial name
- NCT00422994
- Testing
- ropinirole dosing for up to 28 days
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Insufficiency, Pharmacokinetics
A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
1. To investigate the effect of kidney function on the elimination of a single dose of PD 0332334 from the body. 2. To investigate the safety and tolerability of a single dose of PD 0332334 in patients with impaired kidney…
- Trial name
- NCT00721422
- Testing
- PD 0332334
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
- Trial name
- REMODEL (NCT04865770)
- Testing
- Semaglutide
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 106 people
- Sponsor
- Novo Nordisk A/S
AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours after cardiac surgery in patients at risk of developing Cardiac Surgery Associated…
- Trial name
- KIDNEY-II (NCT06811805)
- Testing
- RenalGuard Therapy, Standard of Care (SOC)
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 300 people
- Sponsor
- CardioRenal Systems, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.